Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments.
Substitution of arginine-137 of the vasopressin type 2 receptor (V2R) for histidine (R137H-V2R) leads to nephrogenic diabetes insipidus (NDI), whereas substitution of the same residue to cysteine or leucine (R137C/L-V2R) causes the nephrogenic syndrome of inappropriate antidiuresis (NSIAD). These two diseases have opposite clinical outcomes. Still, the three mutant receptors were shown to share constitutive beta-arrestin recruitment and endocytosis, resistance to vasopressin-stimulated cAMP production and mitogen-activated protein kinase activation, and compromised cell surface targeting, raising questions about the contribution of these phenomenons to the diseases and their potential treatments. Blocking endocytosis exacerbated the elevated basal cAMP levels promoted by R137C/L-V2R but not the cAMP production elicited by R137H-V2R, demonstrating that substitution of Arg137 to Cys/Leu, but not His, leads to constitutive V2R-stimulated cAMP accumulation that most likely underlies NSIAD. The constitutively elevated endocytosis of R137C/L-V2R attenuates the signaling and most likely reduces the severity of NSIAD, whereas the elevated endocytosis of R137H-V2R probably contributes to NDI. The constitutive signaling of R137C/L-V2R was not inhibited by treatment with the V2R inverse agonist satavaptan (SR121463). In contrast, owing to its pharmacological chaperone property, SR121463 increased the R137C/L-V2R maturation and cell surface targeting, leading to a further increase in basal cAMP production, thus disqualifying it as a potential treatment for patients with R137C/L-V2R-induced NSIAD. However, vasopressin was found to promote beta-arrestin/AP-2-dependent internalization of R137H/C/L-V2R beyond their already elevated endocytosis levels, raising the possibility that vasopressin could have a therapeutic value for patients with R137C/L-V2R-induced NSIAD by reducing steady-state surface receptor levels, thus lowering basal cAMP production.
Rochdi
Moulay D
MD
Institut de Recherche en Immunologie et Cancérologie, Département de Biochimie, Université de Montréal, Montréal, Québec, Canada.
Vargas
Gabriel A
GA
Carpentier
Eric
E
Oligny-Longpré
Geneviève
G
Chen
Stanford
S
Kovoor
Abraham
A
Gitelman
Stephen E
SE
Rosenthal
Stephen M
SM
von Zastrow
Mark
M
Bouvier
Michel
M
D019943:Amino Acid Substitution; D001120:Arginine / Q000235:genetics; D001127:Arginine Vasopressin / Q000494:pharmacology; D019390:Arrestins / Q000235:genetics; D002460:Cell Line; D000242:Cyclic AMP / Q000378:metabolism; D018500:Diabetes Insipidus, Nephrogenic / Q000235:genetics*; D006639:Histidine / Q000235:genetics; D006801:Humans; D007177:Inappropriate ADH Syndrome / Q000235:genetics*; D007668:Kidney; D008856:Microscopy, Fluorescence; D016296:Mutagenesis; D009154:Mutation; D010957:Plasmids; D017483:Receptors, Vasopressin / Q000235:genetics*; D014162:Transfection; D000071557:beta-Arrestins
D019390:Arrestins; D017483:Receptors, Vasopressin; D000071557:beta-Arrestins; D001127:Arginine Vasopressin; D006639:Histidine; D001120:Arginine; D000242:Cyclic AMP